secwatch.observer — SEC 8-K summary
======================================

Issuer:     DELCATH SYSTEMS, INC. (DCTH)
CIK:        0000872912
Form:       8-K
Filed at:   2023-03-27T23:59:59+00:00
Accession:  0001193125-23-080510
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Delcath Systems secures up to $85M financing led by Vivo Capital, $25M upfront
------------------------------------------------------------------------------

- Financing includes $24.9M in Series F Convertible Preferred and two warrant tranches totaling $59.8M.
- Tranche A warrants ($34.9M) exercisable until 3/31/2026 or 21 days after FDA approval of HEPZATO.
- Tranche B warrants ($24.9M) exercisable until 3/31/2026 or 21 days after $10M quarterly HEPZATO revenue.
- Conversion and exercise require stockholder approval; funding expected to cover through PDUFA date of Aug 14, 2023 and commercialization.
- Participants include Vivo Capital, Logos Capital, BVF Partners, Stonepine Capital, Serrado Capital, and existing investor Rosalind Advisors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872912/000119312523080510/0001193125-23-080510-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872912/000119312523080510/d382414d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-080510

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer